Ibex Wealth Advisors bought a new stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 74,369 shares of the biopharmaceutical company’s stock, valued at approximately $4,641,000.
Other hedge funds have also made changes to their positions in the company. Pinion Investment Advisors LLC raised its holdings in Bristol Myers Squibb by 3.8% in the 3rd quarter. Pinion Investment Advisors LLC now owns 4,316 shares of the biopharmaceutical company’s stock valued at $269,000 after acquiring an additional 158 shares in the last quarter. Altura Wealth Advisors Inc. lifted its position in shares of Bristol Myers Squibb by 1.2% in the 3rd quarter. Altura Wealth Advisors Inc. now owns 13,717 shares of the biopharmaceutical company’s stock worth $856,000 after acquiring an additional 161 shares during the period. Capital City Trust Co. FL grew its holdings in shares of Bristol Myers Squibb by 0.7% during the 3rd quarter. Capital City Trust Co. FL now owns 23,321 shares of the biopharmaceutical company’s stock worth $1,455,000 after purchasing an additional 167 shares in the last quarter. Eagle Bay Advisors LLC grew its holdings in shares of Bristol Myers Squibb by 2.6% during the 3rd quarter. Eagle Bay Advisors LLC now owns 6,536 shares of the biopharmaceutical company’s stock worth $408,000 after purchasing an additional 168 shares in the last quarter. Finally, Blue Bell Private Wealth Management LLC increased its position in shares of Bristol Myers Squibb by 21.1% during the third quarter. Blue Bell Private Wealth Management LLC now owns 969 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 169 shares during the period. Institutional investors own 76.41% of the company’s stock.
Analyst Ratings Changes
BMY has been the subject of a number of recent research reports. Wells Fargo & Company cut their target price on Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating for the company in a research note on Tuesday, October 13th. JPMorgan Chase & Co. lifted their price target on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. HSBC reiterated a “hold” rating and set a $65.00 price target (up from $60.00) on shares of Bristol Myers Squibb in a research note on Thursday, September 10th. Leerink Partners lowered shares of Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $73.00 to $59.00 in a report on Monday, October 5th. Finally, Raymond James Financial started coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “strong-buy” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $65.46.
Insider Buying and Selling at Bristol Myers Squibb
In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Julia Haller sold 3,800 shares of the business’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the sale, the director owned 30,279 shares in the company, valued at $1,916,963.49. This represents a 11.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.05% of the company’s stock.
Bristol Myers Squibb Price Performance
Shares of BMY stock traded up $1.07 during trading hours on Friday, hitting $63.39. The company had a trading volume of 9,273,842 shares, compared to its average volume of 10,342,026. Bristol Myers Squibb Company has a 12 month low of $45.26 and a 12 month high of $68.64. The firm has a market capitalization of $129.57 billion, a price-to-earnings ratio of 14.06, a PEG ratio of 0.32 and a beta of 0.20. The firm’s fifty day moving average is $61.90 and its 200 day moving average is $60.31. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.10 by $0.25. The business had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. Bristol Myers Squibb’s revenue was up 6.9% on a year-over-year basis. During the same quarter last year, the company earned $1.63 EPS. On average, sell-side analysts predict that Bristol Myers Squibb Company will post 6.46 EPS for the current fiscal year.
Bristol Myers Squibb Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.0%. The ex-dividend date was Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 55.88%.
More Bristol Myers Squibb News
Here’s some of the latest news about BMY:
- Positive Sentiment: Bristol Myers is working to expand Camzyos’ reach, while Eliquis remains an important contributor to its cardiovascular franchise. Sustained growth in these products could help support revenue. Can BMY Sustain Growth in Its Cardiovascular Franchise?
- Neutral Sentiment: The company plans to unify research and development under one structure, aiming to bring scientific and clinical teams together to speed development and use new technologies. The departure of research chief Robert Plenge adds transition risk, so the impact will depend on execution. BMS sets unified research and development structure for 2027
- Negative Sentiment: Zacks Research cut several earnings forecasts, including FY2026 EPS to $6.44 from $6.86 and FY2028 EPS to $4.77 from $5.21; it also reduced its Q4 2026 and Q2 2027 estimates. These revisions point to a softer earnings outlook, although the firm maintained a Hold rating. Bristol Myers Squibb analyst estimates
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
See Also
- Five stocks we like better than Bristol Myers Squibb
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
